Mariner
LPCN icon

Mariner’s Lipocine LPCN Stock Holding History

Mariner’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-804
Closed -$6K – 2791
2022
Q3 		$6K Buy
+804
New +$8.98K ﹤0.01% 2427

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Mariner's LPCN Position: Q4 2022 in Review

Mariner sold out of Lipocine (LPCN) in Q4 2022, closing a stake of 804 shares — an estimated $6K sold.

Mariner first reported a position in LPCN in Q3 2022 and held it in 1 quarter. The position peaked at $6K in Q3 2022. 49 funds tracked by Wall St. Rank hold LPCN as of Q4 2022.

  • Mariner reported no remaining Lipocine position as of Q4 2022 after selling out during the quarter.
  • Mariner sold 804 Lipocine shares in Q4 2022, an estimated $6K.
  • Mariner first reported a position in Lipocine in Q3 2022 and held it in 1 quarter.
  • Mariner's Lipocine position peaked at $6K in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Lipocine as of Q4 2022.

Based on Mariner's 13F filing for Q4 2022, filed 14 Feb 2023.